Prazitone

Prazitone (AGN-511) is a barbiturate derivative developed in the 1970s.[1] Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant.[2] The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.

Prazitone
Clinical data
Other names5-phenyl-5-(2-piperidylmethyl)barbituric acid
ATC code
  • none
Identifiers
  • 5-phenyl-5-(piperidin-2-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC16H19N3O3
Molar mass301.346 g·mol−1
3D model (JSmol)
  • C1CCNC(C1)CC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3
  • InChI=1S/C16H19N3O3/c20-13-16(11-6-2-1-3-7-11,14(21)19-15(22)18-13)10-12-8-4-5-9-17-12/h1-3,6-7,12,17H,4-5,8-10H2,(H2,18,19,20,21,22) ☒N
  • Key:UGZAKKMLMJITLL-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References
  1. DE Patent 1645911
  2. Ross Langlands. Method for imparting anti-depressant and/or anxiolytic effects to animals. US Patent 3,806,596


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.